Authors:

Megan Webb

Date Created:

Not specified

Course Title:

Professor:

Not specified

About Paper:

It is estimated by the World Health Organization that 1 in 100 children have autism spectrum disorder (ASD), a condition characterized by neurological differences that may impact a person's learning or behavior. Clinically, ASD symptoms are alleviated with behavioral or pharmacological therapies, however, not all patients respond to these interventions. Deep brain stimulation (DBS) is a promising treatment of Parkinson's disease that could also be effective in treating ASD. SynGAP1 is a protein involved in neuronal action that is crucial in the regulation of synaptic plasticity. Mutations in the SYNGAP1 gene causing haploinsufficiency can result in the manifestation of ASD symptoms. This study aims at gathering information on the potential of using a Syngap1+/- mouse model to determine whether DBS can counter neurological differences between mice with haploinsufficiency and wild type littermates. Histology slides were analyzed for lesioning from previous surgeries performed in which electrodes were placed for DBS. To gain baseline data before DBS, behavioral tests were conducted on both male and female wild type and Syngap1+/- mice to understand differences. To correlate behavioral results with protein synthesis, labeling of newly synthesized proteins was optimized using azidohomoalanine. While still examining behavioral results, inspection of histology slides showed no evidence of brain lesioning in mice that were to have undergone DBS. Additionally, SDS-PAGE analysis of azidohomoalanine injections revealed more injections administered on subsequent days provides optimal proteomic labeling. With this information as a baseline, further research can be conducted where DBS is performed followed by behavioral studies and proteomic analysis.

Source:

Purdue University / 2023

Topics:

No topics listed

Co-authors:

Megan Webb